Tilray | TRLY - Interest Expense On Debt


Tilray reported $6.7M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 362.52M 357.69M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Aurora Cannabis CAD 2.11M 116K Dec/2025
Avita Medical AUD 1.25M 100K Jun/2025
Canopy Growth CAD 7.34M 1.46M Dec/2025
Cronos Group USD 0 7K Sep/2024
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Divis Laboratories Ltd INR 60M 0 Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
IQVIA Holdings USD 192M 1000K Mar/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Moderna USD 11.49B 36B Mar/2026
Organigram Holdings CAD 179K 127K Mar/2025
Organon & Co USD 128M 3M Sep/2025
Revvity USD 24.72M 1.2M Mar/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Tilray USD 6.7M 2.73M Jun/2025
Viatris USD 120.1M 500K Mar/2026
Xeris Pharmaceuticals USD 7.15M 115K Dec/2025
Zealand Pharma A/S 7.07M 74K Dec/2025